INS and type 1 diabetes mellitus: The most recent study of MDG, evaluating its use in the prevention of exercise-associated hypoglycemia in adults with T1D on continuous subcutaneous insulin infusion (CSII) pumps, was published by Aronson et al in 2023.15 The investigators formulated ready-to-use (room temperature-stable) MDG (150 μg in 30 μL) and matching placebo (30 μL) vials.